Among breast cancers, 20%-25% overexpress the human epidermal growth factor 2 (HER2) receptor that increases tumor aggressiveness.1 HER2-targeted therapies improve pathologic complete remission rate, overall- and disease-free survival in patients with HER2-positive breast cancer.2,3. This evidence concerns the gene ERBB2 and breast carcinoma.